Cat. No：GM-80717AB
Product：Anti-VEGFR2 hIgG1 Antibody(ramucirumab)
Cat. No：GM-80717AB
Product：Anti-VEGFR2 hIgG1 Antibody(ramucirumab)
GM-80717AB-10 10 μg
GM-80717AB-100 100 μg
GM-80717AB-1000 1mg
Species Reactivity Human
Clone Ramucirumab
Source/Isotype Monoclonal human IgG1/κ
Application Bioactivity-ELISA
Specificity Detects VEGFR2
Gene VEGFR2
Other Names CD309, FLK1, VEGFR, KDR
Gene ID 3791 (human)
Background TVEGFR2 (Vascular Endothelial Growth Factor Receptor 2), also known as KDR (Kinase Insert Domain Receptor) or FLK-1, is a key member of the vascular endothelial growth factor receptor family and is primarily expressed on the surface of vascular endothelial cells. As a tyrosine kinase receptor, VEGFR2 binds to its ligands (such as VEGF-A), activating its tyrosine kinase activity and initiating a series of downstream signaling cascades, including the PI3K/AKT, RAS/RAF/MEK/ERK, and PLCγ pathways. These signaling pathways play critical roles in regulating cell proliferation, migration, and survival.Ramucirumab is a monoclonal antibody targeting VEGFR2. By blocking the interaction between VEGF and VEGFR2, it inhibits angiogenesis and has been approved for the treatment of various cancers. This targeted therapeutic strategy has demonstrated significant efficacy in suppressing tumor angiogenesis, thereby preventing tumor growth and metastasis.
Storage Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw.
Formulation Phosphate-buffered solution, pH 7.2.
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
Cat. No：GM-80717AB
Product：Anti-VEGFR2 hIgG1 Antibody(ramucirumab)
GM-80717AB-10 10 μg
GM-80717AB-100 100 μg
GM-80717AB-1000 1mg
Species Reactivity Human
Clone Ramucirumab
Source/Isotype Monoclonal human IgG1/κ
Application Bioactivity-ELISA
Specificity Detects VEGFR2
Gene VEGFR2
Other Names CD309, FLK1, VEGFR, KDR
Gene ID 3791 (human)
Background TVEGFR2 (Vascular Endothelial Growth Factor Receptor 2), also known as KDR (Kinase Insert Domain Receptor) or FLK-1, is a key member of the vascular endothelial growth factor receptor family and is primarily expressed on the surface of vascular endothelial cells. As a tyrosine kinase receptor, VEGFR2 binds to its ligands (such as VEGF-A), activating its tyrosine kinase activity and initiating a series of downstream signaling cascades, including the PI3K/AKT, RAS/RAF/MEK/ERK, and PLCγ pathways. These signaling pathways play critical roles in regulating cell proliferation, migration, and survival.Ramucirumab is a monoclonal antibody targeting VEGFR2. By blocking the interaction between VEGF and VEGFR2, it inhibits angiogenesis and has been approved for the treatment of various cancers. This targeted therapeutic strategy has demonstrated significant efficacy in suppressing tumor angiogenesis, thereby preventing tumor growth and metastasis.
Storage Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw.
Formulation Phosphate-buffered solution, pH 7.2.
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
